Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Chief Legal Officer | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 60,000 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 60,000 · Balance 60,000 F1: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 60,000 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 60,000 · Balance 60,000 F2: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
F2: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 1
1 source rowRow 1 · 2024-08-01 · Disposition to issuer · Disposed 7,527 · Balance 0 F1: Includes 290 shares previously acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2023. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-01 · Disposition to issuer · Disposed 367,126 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 59,171 · Balance 0 F4: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 290 shares previously acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2023.
F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
F4: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 21:19 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164306 · ownership.xml · derivative · entry 2 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-04-16 F2 · derivative.exercise_date: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:19 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164306 · ownership.xml · derivative · entry 1 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-04-16 F1 · derivative.exercise_date: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:34 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerRestricted Stock Units · Derivative | 59,171 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090841 · ownership.xml · derivative · entry 3 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,171 shares Expires not disclosed F4 · derivative.exercise_price: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F4 · derivative.exercise_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F4 · derivative.expiration_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:34 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerStock Option (Right to Buy) · Derivative | 367,126 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090841 · ownership.xml · derivative · entry 2 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 367,126 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:34 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 7,527 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090841 · ownership.xml · nonDerivative · entry 1 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 290 shares previously acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2023. F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 22:31 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 59,171 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-006666 · ownership.xml · derivative · entry 1 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,171 Underlying: Common Stock · 59,171 shares Expires not disclosed F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.exercise_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.expiration_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 01:21 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 7,072 | $41.42 | $292,944.87 |
DisclosureSEC source: 0000950170-23-072375 · ownership.xml · nonDerivative · entry 2 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,237 F3 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.36 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2023 Filed Dec 22, 2023 01:21 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionRestricted Stock Units · Derivative | 13,796 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-072375 · ownership.xml · derivative · entry 3 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,796 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.exercise_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.expiration_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. Read SEC document |
| December 19, 2023 Filed Dec 22, 2023 01:21 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 13,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-072375 · ownership.xml · nonDerivative · entry 1 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F2 · price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 00:45 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0000950170-23-068887 · ownership.xml · derivative · entry 6 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 254,262 Underlying: Common Stock · 10,000 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 00:45 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 10,000 | $41.37 | $413,700.00 |
DisclosureSEC source: 0000950170-23-068887 · ownership.xml · nonDerivative · entry 4 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 513 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 00:45 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 10,000 | $13.17 | $131,700.00 |
DisclosureSEC source: 0000950170-23-068887 · ownership.xml · nonDerivative · entry 3 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 00:45 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0000950170-23-068887 · ownership.xml · derivative · entry 5 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,262 Underlying: Common Stock · 7,500 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 00:45 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 7,500 | $35.00 | $262,500.00 |
DisclosureSEC source: 0000950170-23-068887 · ownership.xml · nonDerivative · entry 2 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 513 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 00:45 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 7,500 | $13.17 | $98,775.00 |
DisclosureSEC source: 0000950170-23-068887 · ownership.xml · nonDerivative · entry 1 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 4, 2023 adopted by the Reporting Person. F2 · balance_after: Includes 513 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 01:29 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 13,796 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004362 · doc4.xml · derivative · entry 2 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,796 Underlying: Common Stock · 13,796 shares Expires not disclosed F2 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 01:29 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 54,292 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0000899243-23-004362 · doc4.xml · derivative · entry 1 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,292 Underlying: Common Stock · 54,292 shares Expires 2033-02-06 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 01:18 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0000899243-22-028185 · doc4.xml · derivative · entry 3 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,762 Underlying: Common Stock · 10,000 shares Expires 2031-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2022 adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 01:18 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 10,000 | $40.00 | $400,001.00 |
DisclosureSEC source: 0000899243-22-028185 · doc4.xml · nonDerivative · entry 2 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2022 adopted by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 - $40.07. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 01:18 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 10,000 | $13.17 | $131,700.00 |
DisclosureSEC source: 0000899243-22-028185 · doc4.xml · nonDerivative · entry 1 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2022 adopted by the Reporting Person. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:43 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 58,572 | $0.00 Strike: $30.36 | $0.00 |
DisclosureSEC source: 0000899243-22-005933 · doc4.xml · derivative · entry 1 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,572 Underlying: Common Stock · 58,572 shares Expires 2032-02-09 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:34 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 281,762 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0000899243-21-021801 · doc4.xml · derivative · entry 1 Akamine Scott · CIK 0001816720 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,762 Underlying: Common Stock · 281,762 shares Expires 2031-06-01 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.